BAN2401

Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news.  The Analysts Raymond James' Laura Chico maintained a Market...

Shares of Biogen Inc (NASDAQ: BIIB) soared higher by more than 13 percent early Friday morning in reaction to the results of an Alzheimer's disease study.  What Happened Biogen and its Japanese partner Eisai Co released a final analysis of 856 patients in a Phase 2 clinical study in...

Baird's Brian Skorney reiterated Biogen Inc (NASDAQ: BIIB)'s Neutral rating with a $268 price target. The reiteration came after Biogen's roadshow. "We continue to see the firm facing headwinds towards the back half of the year as MS sales flatten and clinical data catalysts dry up," said the...